BioCardia (BCDA) Regains Nasdaq Compliance; Listing Continues

BioCardia, Inc. announced that on October 2, 2025 it received formal written notice from The Nasdaq Stock Market staff that the company has regained compliance with Listing Rule 5550(b)(1).

Rhea-AI Filing Summary

BioCardia, Inc. announced that on October 2, 2025 it received formal written notice from The Nasdaq Stock Market staff that the company has regained compliance with Listing Rule 5550(b)(1). As a result, the company's common stock will continue to be listed on The Nasdaq Stock Market. The filing states a press release describing the action is attached as Exhibit 99.1 to the current report. The notice signals Nasdaq’s staff has accepted whatever corrective steps the company previously took to meet the Equity Rule and preserves the company’s ongoing access to Nasdaq’s market for its common shares.

Positive

• Regained compliance with Nasdaq Listing Rule 5550(b)(1)
• Common stock will continue to be listed on The Nasdaq Stock Market
• Press release attached as Exhibit 99.1 for further detail

Negative

• The company previously failed to meet the applicable Nasdaq standard and only now has regained compliance
• The filing contains no financial statements or additional details about the corrective actions taken

Insights

Corporate Governance Analyst

Regaining Nasdaq compliance removes an immediate listing risk.

The company states it has regained compliance with Listing Rule 5550(b)(1), which relates to minimum bid price or similar equity listing standards. Continued listing preserves liquidity and the regulatory status of the common stock.

This outcome matters because resolving compliance issues avoids potential suspension or delisting, which can restrict shareholder trading and increase costs of capital.

Equity Markets Analyst

Market access is maintained; near-term operational impact is limited.

The Nasdaq staff’s notice means the company’s shares will remain listed on The Nasdaq Stock Market, retaining the exchange’s visibility and potential investor pool for BCDA.

The filing includes a press release as Exhibit 99.1; investors can review that for details on the remedial steps. No financial statements or guidance were included in this report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCardia (BCDA) disclose about Nasdaq compliance?

The company disclosed it has regained compliance with Nasdaq Listing Rule 5550(b)(1) and that its common stock will continue to be listed.

When did BioCardia say it regained Nasdaq compliance?

The company stated it received formal written notice from Nasdaq on October 2, 2025 that it had regained compliance.

Does the 8-K include financial details about the compliance action for BCDA?

No. The 8-K attaches a press release as Exhibit 99.1 but does not include financial statements or detailed remediation steps.

Will BioCardia’s stock remain listed on Nasdaq after the notice?

Yes. The filing states the company’s common stock will continue to be listed on The Nasdaq Stock Market.

Where can investors find more information about the Nasdaq notice for BCDA?

The filing indicates a press release dated October 2, 2025 is attached as Exhibit 99.1 to the current report for additional details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 08:00 AM Learn about SEC filing dates

false 0000925741 0000925741 2025-10-02 2025-10-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2025

BIOCARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38999		23-2753988
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

320 Soquel Way
Sunnyvale, California 94085

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01   Other Events.

On October 2, 2025, BioCardia, Inc. (the “Company”) issued a press release announcing that it received formal written notice from The Nasdaq Stock Market, LLC’s Staff that the Company has regained compliance with Listing Rule 5550(b)(1) (the “Equity Rule”) of the Nasdaq Stock Market. Accordingly, the Company’s common stock will continue to be listed on The Nasdaq Stock Market.

A copy of the press release is attached as Exhibit 99.1 to the current report on Form 8-K.

Item 9.01   Financial Statements and Exhibits.

d) Exhibits

Exhibit Number		Description
99.1		BioCardia, Inc. press release dated October 2, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.

/s/ Peter Altman, Ph.D.

Peter Altman, Ph.D.

President and Chief Executive Officer

Date: October 2, 2025